English 
繁體中文 
Recent Posts
- The Investigational Oral Anti-Cancer Drug CVM-1118 Receives NMPA Approval to Initiate a Phase II Clinical Trial for Intermediate-Stage Liver Cancer in China.
- 本公司抗癌口服研發中新藥 CVM-1118用於治療中期肝癌，獲中國國家藥品監督管理局核准執行第二期臨床試驗。
- TaiRx’s New Drug CVM-1118 Granted Orphan Drug Designation for Pancreatic Neuroendocrine Tumors (PNETs), Securing Seven Years of Market Exclusivity in the U.S.
- 台睿新藥CVM-1118取得胰腺神經內分泌腫瘤(PNETs)孤兒藥資格，未來上市享美國7年市場專賣獨佔權
- 本公司股務代理機構營業處所遷址公告
Post Archive
- 2025 年 November
- 2025 年 February
- 2025 年 January
- 2024 年 November
- 2024 年 July
- 2024 年 May
- 2023 年 January
- 2022 年 December
- 2022 年 May
- 2020 年 December
- 2020 年 November
- 2020 年 March
- 2019 年 December
- 2019 年 August
- 2019 年 January
- 2018 年 October
- 2018 年 April
- 2018 年 March
- 2017 年 October
- 2017 年 August
- 2017 年 June
- 2016 年 June
- 2016 年 March
- 2015 年 December
- 2015 年 September
- 2015 年 July
- 2015 年 May
- 2014 年 March
- 2014 年 January
- 2013 年 December
Catogery Tags
Connect With Us
-
The Investigational Oral Anti-Cancer Drug CVM-1118 Receives NMPA Approval to Initiate a Phase II Clinical Trial for Intermediate-Stage Liver Cancer in China.
The anti-cancer drug, CVM-1118, has received approval f…
-
TaiRx’s New Drug CVM-1118 Granted Orphan Drug Designation for Pancreatic Neuroendocrine Tumors (PNETs), Securing Seven Years of Market Exclusivity in the U.S.
TaiRx’s orally administered anticancer drug, CVM-1118 (…
-
-
TaiRx‘s injectable product, Zelnite®, has been approved by TFDA to add high dosage and change drug labeling
In 2018, TaiRx received approval from the Food and Drug…
-
TaiRx’s sodium selenite pentahydrate—SelenOne®—earned the Symbol of National Quality (SNQ) in 2022 for its affirmed safety and quality for use as a food additive.
In December 2022, TaiRx’s proprietary sodium selenite p…
-
Mr. Andrew Lin’s appointment as Chairman of TaiRx, Inc. is effective as of December 9, 2020.
Andrew Lin received his master’s degree of Business Adm…
-
TaiRx’s anti-cancer drug CVM-1118 won the renewal of Excelsior Award in 2020.
Having been awarded the 12th National Innovation Award …
-
TaiRx successfully raised 504 million NTD in capital.
To enrich working capital, TaiRx has successfully raise…
-
TaiRx ranked first in Taiwan for the most innovative pharmaceutical companies in the APAC region
World-renowned professional information services compan…
-
TaiRx receives “Technology and Product or Technology Development is Successful and Marketable” recommendation from Industrial Development Bureau and starts CVM-1118 (Foslinanib) Phase II clinical trial in Taiwan and US.
TaiRx, Inc. (6580) announces good news at the start of …
